Popular, Inc., through its subsidiaries, provides various retail, mortgage, and commercial banking services for individuals and businesses in Puerto Rico, the United States, the British Virgin Islands, the Caribbean, and…
FAIL · Does not pass the screen
156.52 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 04:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price156.52 USD at the 6 Nov 2026 close
Our value readUndervalued vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.74, read 2026-11-08
Ethical does not pass the values gate
Price156.52 USD
Fair value216.00
Ethical score30.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-29Read Accumulation157.88-0.9% to today Markdown gives way to Accumulation after a 10% slide in 10 weeks
2026-08-23Read Markdown176.14-11.1% to today ✓Accumulation gives way to Markdown after a 9% rise in 7 weeks
2026-07-02Read Accumulation160.95-2.8% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Popular Inc holds its Accumulation at $156.52. Consolidating, no directional conviction, held for 61 days.
As held on the ledger · 2026-11-06
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 61 days
Price at the screen
$156.52
Valuation
9.89 trailing · 8.97 forward price to earnings
Values screen
FAIL· score 30.0
Beta
0.64
The Workings
Five Screens, Shown in Full
Does not pass. Excluded industry: Banks - Regional
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Excluded industry: Banks - Regional
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Popular does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BPOP's ethical verdict changes
Today BPOP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 28% discount to our $216.00 fair value, weak competitive moat, 9.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 27.5% discount to the base estimate.
Where our models see it going: fair-value estimate $216.00, with a range of $196.52 to $313.04, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Local banking that hits an ethical wall
Families in Puerto Rico and the Caribbean turn to Popular for mortgages, deposits and small business loans that bigger names often overlook. The numbers show steady 10% revenue growth, a 30% profit margin and 15% ROE at a forward multiple of 10.3x. Yet the opportunity rating sits at none.
We pass outright because the ethical screen excludes regional banks on principle. No valuation discount or analyst target near 189 changes that line. The weak moat simply reinforces the decision.
Risk sits in the usual cyclical pressures of lending, currency moves across Latin America and the fact that low multiples on banks often signal peak-cycle earnings rather than bargains. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BPOP trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Accumulation$158.72+0.5%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171.
2026-10-22Markdown$158.89+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$158.89+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$158.89+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$158.89+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$158.89+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown$158.89+1.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$157.37+0.7%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$156.29+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it none, with a mean price target of $171. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
